arrow
J

Jorge Labrador

hospital universitario de burgos
H指数:24
被引数:2,463

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Measurable residual disease assessment as an early end point of treatment efficacy in acute myeloid leukemia: a multinational PETHEMA study of 2623 patients treated with intensive therapy

可测量残留病灶评估作为急性髓系白血病治疗早期疗效终点:一项多国PETHEMA研究,纳入2623例接受强化疗的患者

Leukemia
IF13.4
2026-10-080
PRE
Venetoclax-based therapy versus hypomethylating agents alone in unfit patients with newly diagnosed acute myeloid leukemia: a real-world study from the PETHEMA registry

维奈克拉为基础的治疗与单用去甲基化药物在初诊急性髓系白血病不适宜患者中的比较:一项来自PETHEMA登记研究的真实世界研究

Leukemia
IF13.4
2026-10-060
OA
Real-World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: The PETHRATIFY Study
2026-09-010
OAAI
Impact of molecular profiling in patients with acute myeloid leukemia undergoing allogeneic transplantation in first remission: a study by the PETHEMA group

急性髓系白血病患者在首次缓解期接受 allo 移植时分子分型的临床影响:PETHEMA 小组的研究

2026-05-070
PRE
Impact of CYP and ABCB1 Polymorphisms on Bortezomib-Induced Adverse Events in Multiple Myeloma

CYP和ABCB1基因多态性对硼替佐米诱导的多发性骨髓瘤不良事件的影响

2026-04-040
OAAI
Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry

自体干细胞移植与强化疗巩固治疗急性髓系白血病患者的长期获益:一项来自PETHEMA AML登记研究的倾向性评分匹配分析

Leukemia
IF13.4
2025-09-010
OAAI
Effectiveness of Stem Cell Secretomes in the Regeneration and Functional Recovery of Severed Nerves in Patients with Nerve Injuries: A Systematic Review

干细胞分泌组在促进神经损伤患者受损神经的再生和功能恢复中的有效性:一项系统评价

CELLS
IF5.2
2025-03-250
OA
Autologous or Allogeneic Hematopoietic Stem Cell Transplantation as Front-Line Treatment for Adult Secondary Acute Myeloid Leukemia Patients: The PETHEMA Registry Experience

自体或异基因造血干细胞移植作为成人继发性急性髓系白血病患者的首线治疗:PETHEMA登记研究经验

2025-02-010
PRE
Treatment patterns and outcomes in secondary acute myeloid leukemia arising after hypomethylating agents: PETHEMA registry study

低甲基化药物引起的继发性急性髓细胞性白血病的治疗模式和结果: PETHEMA注册研究

CANCER
IF5.1
2025-01-020
PRE
Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023-2024: EPICOVIDEHA-EPIFLUEHA Report
2024-12-230
OAAI
Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL

慢性淋巴细胞白血病患者的治疗策略和治疗顺序: 欧洲CLL研究计划ERIC的国际研究

2024-09-170
OAAI
Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein Vaccine when Co-administered with Adjuvanted Seasonal Quadrivalent Influenza Vaccine in Older Adults: A Phase 3 Randomized Trial

呼吸道合胞病毒融合前F蛋白疫苗联合佐剂季节性四价流感疫苗在老年人中的安全性和免疫原性: 一项3期随机试验

2024-08-057
OAAI
Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy
2024-06-191
OAAI
Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry
CANCER
IF5.1
2024-06-191
PRE
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey (vol 52, pg 1125, 2024)

重症新型冠状病毒肺炎和血液系统恶性肿瘤患者的ICU需求和结局: EPICOVIDEHA调查结果 (第52卷,1125页,2024页)

2024-05-210
OAAI
Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022
2024-05-015
OAAI
Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry

地塞米松治疗新型冠状病毒肺炎与血液系统恶性肿瘤患者的死亡率增加有关: EPICOVIDEHA注册表的结果

2024-04-042
OAAI
CD8+NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma
2024-02-263
OAAI
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

重症新型冠状病毒肺炎和血液系统恶性肿瘤患者的ICU需求和结局: EPICOVIDEHA调查的结果

2024-02-224
OAAI